Alliancebernstein L.P. lifted its holdings in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 1.9% during the first quarter, Holdings Channel.com reports. The firm owned 84,200 shares of the biopharmaceutical company’s stock after acquiring an additional 1,600 shares during the quarter. Alliancebernstein L.P.’s holdings in MacroGenics were worth $2,682,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of MGNX. Victory Capital Management Inc. lifted its holdings in shares of MacroGenics by 1,751.6% during the first quarter. Victory Capital Management Inc. now owns 1,246,669 shares of the biopharmaceutical company’s stock worth $39,706,000 after purchasing an additional 1,179,339 shares during the period. BlackRock Inc. lifted its holdings in shares of MacroGenics by 6.8% during the fourth quarter. BlackRock Inc. now owns 5,104,831 shares of the biopharmaceutical company’s stock worth $116,697,000 after purchasing an additional 323,240 shares during the period. Baker BROS. Advisors LP acquired a new position in shares of MacroGenics during the fourth quarter worth $4,588,000. Tudor Investment Corp Et Al acquired a new position in shares of MacroGenics during the fourth quarter worth $3,111,000. Finally, Panagora Asset Management Inc. lifted its holdings in MacroGenics by 55.2% in the fourth quarter. Panagora Asset Management Inc. now owns 317,606 shares of the biopharmaceutical company’s stock valued at $7,260,000 after buying an additional 112,988 shares during the period. Institutional investors own 94.45% of the company’s stock.
MGNX opened at $21.90 on Friday. The firm has a fifty day moving average of $30.91. The company has a market capitalization of $1.31 billion, a P/E ratio of -8.83 and a beta of 2.28. MacroGenics, Inc. has a 1-year low of $18.16 and a 1-year high of $36.48.
Several equities analysts recently issued reports on the stock. HC Wainwright boosted their target price on shares of MacroGenics from $36.00 to $41.00 and gave the company a “buy” rating in a report on Friday, April 30th. SVB Leerink boosted their target price on shares of MacroGenics from $37.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, April 30th. Wedbush decreased their price target on shares of MacroGenics from $39.00 to $34.00 and set an “outperform” rating for the company in a research note on Monday. Barclays raised shares of MacroGenics from an “underweight” rating to an “overweight” rating and lifted their price target for the company from $14.00 to $40.00 in a research note on Friday, March 12th. Finally, Zacks Investment Research downgraded shares of MacroGenics from a “hold” rating to a “sell” rating in a research note on Tuesday, May 4th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $31.29.
In other news, SVP Thomas Spitznagel sold 5,000 shares of the business’s stock in a transaction dated Thursday, April 15th. The shares were sold at an average price of $30.91, for a total transaction of $154,550.00. Following the completion of the sale, the senior vice president now directly owns 5,000 shares of the company’s stock, valued at $154,550. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO James Karrels sold 15,000 shares of the business’s stock in a transaction dated Monday, March 22nd. The stock was sold at an average price of $33.00, for a total transaction of $495,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 23,917 shares of company stock valued at $774,894. 7.90% of the stock is currently owned by insiders.
MacroGenics Company Profile
MacroGenics, Inc, a biopharmaceutical company, discovers and develops antibody-based therapeutics to treat cancer in the United States. The company's approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.
Recommended Story: Most Volatile Stocks – What Investors Need to Know to Maximize ROI
Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics, Inc. (NASDAQ:MGNX).
Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.